Drug Database
TE

tenofovir disoproxil orotate (Virreal)

✓ Approved

Dong-A ST · · 小分子

什么是 tenofovir disoproxil orotate?

tenofovir disoproxil orotate 是一种小分子,由Dong-A ST研发。该药已获批,用于治疗相关适应症,给药途径:Oral (PO)。

药物档案

商品名Virreal
公司Dong-A ST
药物类别小分子
分子靶点,
给药途径Oral (PO)
状态Approved

作用机制

分子靶点

tenofovir disoproxil orotate 作用于 2 个分子靶点:

gag-pol, HIV-1 (gag-pol)
(P)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

tenofovir disoproxil orotate 针对 2 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Infections and infestationsAcquired immunodeficiency syndrome✓ Approved
Infections and infestationsHepatitis B✓ Approved

相关研究文献

PubMedBMC infectious diseases2026-11-19

Effectiveness of a direct switch to Bictegravir/Emtricitabine/Tenofovir alafenamide in people living with HIV experiencing first-line treatment failure: a real-world study.

Yin Min M, Li Fei F, Zhang Qian Q, Yuan Ziqing Z

In China, Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)- or Protease Inhibitor (PI)/boosted regimens with two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) are common first-line Antiretroviral Therapy (ART) for People living with HIV (PLWH). Genotypic resistance testing is often unavailable or delayed after treatment failure. The effectiveness of direct switch to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) following first-line failure in Chinese PLWH is uncertain and requires further investigation. A total of 68 PLWH with plasma HIV RNA > 200 copies/mL while receiving first-line ART were directly switched to B/F/TAF between January 2022 and December 2023. Genotypic resistance testing was performed in individuals with viral load (VL) > 1000 copies/mL. Virologic suppression, CD4 cell recovery, and adverse events were evaluated at week 24 (W24) and 48 (W48). There were 61 (90%) on NNRTI-based regimens and 7 (10%) on PI-based regimens at baseline. Among 49 individuals with VL > 1000 copies/mL, 21(42.9%) had NRTI RAMs, 26(53.0%) had NNRTI RAMs, 3(6.1%) had PI-related mutations. The intention-to-treat (ITT) analysis indicated the virologic suppression rate was 61.7% (42/68) at W24 and 72.1%(49/68) at W48. Meanwhile, the per-protocol (PP) analysis indicated the virologic suppression rate was 93.3%(42/45) at W24 and 100% (49/49) at W48. Notably, the cohort included participants with pre-existing NRTI/NNRTI RAMs. Most mutation carriers achieved virologic suppression after regimen switching.The median CD4 count was increased from 199 [interquartile range(IQR): 85-347] cells/µL at W0 up to 346 (IQR: 178-507) cells/µL at W24 and 410(IQR:200-577) cells/µL at W48 (P = 0.002, P < 0.001, respectively). Our study indicated that direct switch to B/F/TAF after first-line treatment failure achieved 72.1% virological suppression rate in ITT analysis and 100% virologic suppression rate in PP analysis at W48, suggesting that B/F/TAF may serve as an effective salvage therapy for PLWH with pre-existing NRTI RAMs in China in the setting of genotypic resistance testing is unavailable timely.

PMID 43052820
阅读全文 →
PubMedAIDS (London, England)2026-11-18

Diagnostic accuracy of point-of-care urine tenofovir test, and associations between metrics of tenofovir use and treatment outcomes in a community ART programme.

Naidu Lisanthini L, Tlhaku Kwena K, Govender Katya K, Sookrajh Yukteshwar Y et al.

Urine tenofovir (uTFV) and dried blood spot (DBS) tenofovir diphosphate (TFV-DP) concentrations respectively estimate short- and medium-term adherence to tenofovir disoproxil fumarate (TDF)-based antiretroviral therapy (ART). We evaluated the accuracy of a point-of-care uTFV assay, and associations between uTFV/TFV-DP, and viral load and retention outcomes within a South African community ART programme. We measured uTFV and DBS TFV-DP concentrations using liquid chromatography-tandem mass spectrometry (LC-MS/MS). We calculated sensitivity and specificity of the point-of-care uTFV assay at the manufacturer-recommended threshold of ≥1500 ng/ml compared to LC-MS/MS. We assessed associations of the point-of-care uTFV assay, and DBS TFV-DP concentrations with concurrent viraemia, and with retention-in-care by 16weeks post-enrolment. Of 196 adults, median age was 44 years, 64.8% (127) were female, and 97.4% (191) were receiving TDF. One hundred and eighty-five (94.4%) had detectable point-of-care uTFV, which had high sensitivity (99.5%, 95% CI 96.5-100%) and moderate specificity (76.9%, 95% CI 46.0-93.8%) for detecting uTFV ≥1500 ng/ml. Two participants had concurrent viraemia ≥1000 copies/ml; of these 50.0% (1/2) (95% CI 9.4-90.5) had undetectable point-of-care uTFV, and 100% (2/2) (95% CI 19.7-100) had TFV-DP <483 fmol/punch. Among participants without viraemia, 97.4% (184/189) (95% CI 93.6-99.0) had detectable uTFV, and 98.4% (186/189) (95.3-99.6) had TFV-DP ≥483 fmol/punch. Point-of-care uTFV and DBS TFV-DP were not associated with retention-in-care. The point-of-care uTFV assay demonstrated high sensitivity and moderate specificity to detect uTFV. Over 95% of people without viraemia had detectable point-of-care uTFV or high DBS TFV-DP levels, respectively, but these were not associated with 16-week retention-in-care.

PMID 43049072
阅读全文 →
PubMedAIDS (London, England)2026-11-18

Impact of dynamic choice of delivery of oral preexposure prophylaxis during the postpartum period in South Africa.

Joseph Davey Dvora D, Bheemraj Kalisha K, Dadan Sumaya S, Dovel Kathryn K et al.

Providing dynamic choice in preexposure prophylaxis (PrEP) delivery may improve PrEP use among postpartum women who discontinued PrEP in pregnancy. Randomized control trial. Between April 2023 and May 2025, we enrolled postpartum women without HIV, >15 years old, previously enrolled in a PrEP trial in pregnancy who discontinued PrEP for >3 months, willing to restart PrEP. Participants were randomized 1 : 1 to PrEP-Choice (choice of rapid PrEP pick-up from clinic, community, or home-delivery, with HIV self-testing in any choice) vs. Enhanced-Counseling arm (clinic-based PrEP distribution and counseling with biofeedback from urine tenofovir testing). Primary outcome was PrEP use through 6 months defined as PrEP collection and use (self-reported) at baseline, 3 and 6 months using logistic regression via intention to treat analysis. Secondary outcomes included urine tenofovir-confirmed adherence at 6 months and PrEP use aligned with sex-activity. We enrolled 266 postpartum women who previously discontinued PrEP (n = 134 PrEP-Choice; n = 132 Enhanced-Counseling). Median age was 25-years [interquartile range (IQR) 21-30], median postpartum time was 4-months (IQR = 3-7), median time since last PrEP use was 2.9-months (IQR = 2.7-4.4). Within Choice-Arm, 49% selected rapid clinic pick-up (n = 65), 46% home delivery (n = 62), 5% community pick-up (n = 7); 45% (n = 59) switched delivery method at least once during trial. At 6 months, 42% in the Choice-Arm collected PrEP and reported use in past month vs. 38% in Enhanced-Counseling [odds ratio (OR) = 1.74; 95% confidence interval (CI) = 1.06-2.88]. Results were consistent in women reporting recent sex (OR = 1.74; 95% CI = 0.92-3.32). There was no difference by arm in objective PrEP use at 6 months: 15% had positive urine tenofovir tests in Choice vs. 13% in Enhanced-Counseling arm (OR = 1.20; 95% CI = 0.60-2.43). Offering dynamic choice in PrEP delivery increased continuation and reported PrEP use in postpartum women vs. biofeedback-enhanced counseling; although objectively-measured adherence was similar across arms.

PMID 43049077
阅读全文 →
PubMedJGH open : an open access journal of gastroenterology and hepatology2026-11-18

Long-Term Five-Year Effectiveness of Tenofovir Alafenamide in Japanese Patients With Chronic Hepatitis B: A Prospective Multicenter Registry Study.

Takada Hitomi H, Tamaki Nobuharu N, Ochi Hironori H, Marusawa Hiroyuki H et al.

Tenofovir alafenamide (TAF) is recommended as a first-line therapy for chronic hepatitis B (CHB); however, long-term real-world data in Japan are limited. This study aimed to evaluate the 5-year efficacy of TAF in a multicenter cohort. This prospective multicenter registry study included 638 patients with CHB who initiated TAF therapy between March 2019 and March 2025. The primary outcomes were the HBV-DNA suppression rate and alanine aminotransferase (ALT) normalization rate at 5 years. Subgroup analyses were performed according to treatment history, disease stage, and renal function. The HBV-DNA suppression rate increased over time and reached 97% at 5 years. Comparable suppression rates were observed between treatment-naïve patients and patients switched from other nucleos(t)ide analogues (NAs) to TAF (97% vs. 97%, p = 1.0), as well as between patients with chronic hepatitis and those with liver cirrhosis (97% vs. 100%, p = 0.60). The overall ALT normalization rate at 5 years was 84%. Among patients switched from other NAs to TAF with detectable HBV-DNA at baseline, 87% achieved viral suppression. In patients with renal impairment (eGFR < 60 mL/min/1.73 m2), the suppression rate was 97%, comparable to those with normal renal function (97%, p = 1.0). TAF demonstrated sustained and high antiviral efficacy over 5 years in a real-world Japanese cohort, including in patients switched from other nucleos(t)ide analogues and those with renal impairment. These findings support the long-term effectiveness of TAF across a broad spectrum of patients with CHB in routine clinical practice.

PMID 43047559
阅读全文 →
PubMedMalawi medical journal : the journal of Medical Association of Malawi2026-11-18

The First Extensively Drug-Resistant (XDR) Tuberculosis Patient Diagnosed in Malawi - a Case Report.

Talama George C GC, Kadyeremwana Bright B, Kwenje Charles C, Mtalika Sosten S et al.

We report the first case of extensively drug-resistant (XDR) TB diagnosed in Malawi. A 43-year-old female living with HIV, on tenofovir-lamivudine-dolutegravir antiretroviral therapy, with long-term viral suppression, accumulated resistance to rifampicin, levofloxacin, and linezolid on successive TB treatment regimens between 2018 and 2024, qualifying as XDR-TB. Throughout treatment as an outpatient, she regularly missed TB visits and reported poor TB drug adherence, mainly related to alcohol abuse and inconsistent availability of funds for transport. After XDR-TB diagnosis, the patient, guardians, treatment providers, and health facility leadership agreed to management as an inpatient in August 2024, when she started an 18-month regimen of bedaquiline-delamanid-cycloserine-clofazimine-pyrazinamide, with good treatment outcome. The emergence of XDR-TB in Malawi calls for further scale-up of TB resistance testing and structured approaches to improving drug adherence among drug-resistant TB patients.

PMID 43047292
阅读全文 →
PubMedBritish journal of clinical pharmacology2026-11-16

Rifampicin and long-acting cabotegravir-rilpivirine: Therapeutic drug monitoring-guided management of a major drug-drug interaction-A case report.

Ciullini Lorenzo L, Thoueille Paul P, Marzolini Catia C, Marinosci Annalisa A

Long-acting injectable cabotegravir/rilpivirine (LAI CAB/RPV) is subject to clinically significant drug-drug interactions with strong enzyme inducers such as rifampicin due to markedly reduced drug exposure and potential development of resistance. However, real-world evidence on managing this interaction remains scarce. We report a person with HIV, virologically suppressed on LAI CAB/RPV, who developed an orthopaedic implant-associated infection requiring 10-week rifampicin-containing therapy for its antibiofilm activity. Further LAI CAB/RPV injections were withheld, and oral tenofovir disoproxil fumarate/emtricitabine once daily plus dolutegravir 50 mg twice daily was initiated. This regimen was continued until 3 weeks after rifampicin discontinuation; afterwards, dolutegravir was reduced to once daily. LAI CAB/RPV was restarted 5 weeks after rifampicin withdrawal; oral antiretroviral therapy was discontinued. Serial therapeutic drug monitoring (TDM) showed a rapid decline in plasma CAB and RPV concentrations from day 8 after rifampicin initiation, with both drugs falling below the efficacy thresholds by day 10. In contrast, tenofovir and dolutegravir concentrations remained within the therapeutic range during rifampicin co-administration, whereas twice-daily dolutegravir concentrations exceeded the therapeutic range 3 weeks after rifampicin discontinuation. HIV RNA remained undetectable throughout follow-up. This case confirms the clinically relevant interaction between rifampicin and LAI CAB/RPV, as illustrated by the rapid decline in residual CAB and RPV plasma concentrations following rifampicin initiation. Temporary substitution with a recommended first-line oral antiretroviral regimen maintained adequate drug exposure, was well tolerated and preserved virological suppression throughout rifampicin treatment. TDM allowed to characterize the interaction and may support individualized management in selected complex clinical situations.

PMID 43035988
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多tenofovir disoproxil orotate